Major Company Announces $650 Million Investment In Groton

Freedom Broker raised Pfizer's (PFE) price target to $34, citing strong Q3 2026 results with revenue of $16.6B and EPS of $0.87, both exceeding estimates. The company also raised its full-year guidance. Argus also raised its target to $40. PFE shares are up 26% YTD and offer a 5.76% dividend yield.

Pfizer Korea's Litfulo (ritlecitinib tosylate) cleared a reimbursement review for severe alopecia areata in adults and adolescents aged 12+ by the Health Insurance Review and Assessment Service. The decision may improve treatment access, but coverage depends on further steps, including price negotiations. Litfulo is a once-daily oral treatment that promotes hair regrowth by blocking inflammatory signals.

Pfizer plans to invest $650 million in a new Manufacturing Technology Center in Groton, Connecticut. The 220,000-square-foot facility will support clinical drug production, with construction starting in Q2 2027 and operations beginning in mid-2031. Local officials highlight the long-term commitment to the region and job creation.

Pfizer plans to invest $650 million over five years to build a 220,000-square-foot Manufacturing Technology Center in Groton. The facility will support clinical trials and consolidate employees from other campus buildings. Construction is set to begin in Q2 2027, with operations starting in mid-2031. The Groton campus is a key R&D hub for Pfizer, employing around 4,000 people.

Pfizer plans to invest $650 million over five years to build a 220,000-square-foot Manufacturing Technology Center in Groton, Connecticut. The facility will support clinical trials and consolidate employees from other campus locations. Construction is set to begin in Q2 2027, with operations starting in mid-2031. Pfizer had 2025 revenues of $63 billion and ranks No. 73 on the Fortune 500.

Pfizer plans to invest $650M in a 220,000-square-foot manufacturing technology center at its Groton, Conn., campus. The facility, set to open in 2031, will produce pharmaceutical ingredients and support clinical trials. The project aims to modernize Pfizer's workforce and infrastructure, consolidating operations from other campus facilities.